Table 1.
Normal Flow Group (n = 169) | Slow/No‐Reflow Group (n = 41) | P Value | |
---|---|---|---|
Age (yrs) | 61.1 ± 12.4 | 67.1 ± 14.9 | 0.031 |
Male sex | 103 (60.8%) | 29 (70.0%) | 0.494 |
Hypertension | 79 (46.7%) | 25 (60.5%) | 0.968 |
Hyperlipidemia | 80 (47.2%) | 23 (55.4%) | 0.174 |
Current smoker | 95 (56.3%) | 25 (61.5%) | 0.711 |
Diabetes mellitus | 26 (15.6%) | 8 (19.5%) | 0.635 |
Left ventricular ejection fraction (%) | 56.9 ± 8.1 | 45.5 ± 7.2 | 0.025 |
Time to reperfusion (h) | 5.4 ± 2.8 | 6.7 ± 3.2 | 0.037 |
WBC count on admission (/mm3) | 10484 ± 2716 | 10562 ± 3075 | 0.901 |
CRP on admission (mmol/L) | 5.7 ± 4.3 | 5.9 ± 5.4 | 0.861 |
Glucose on admission (mmol/L) | 8.7 ± 4.1 | 12.4 ± 7.5 | 0.012 |
Peak creatine kinase levels (IU/L) | 320.2 ± 2570 | 408.9 ± 2117 | 0.582 |
LDL‐C (mmol/L) | 2.9 ± 0.9 | 3.5 ± 1.1 | 0.016 |
In‐hospital medication | |||
Aspirin | 161 (95.2%) | 40 (97.3%) | 0.404 |
ACEI or ARB | 129 (76.4%) | 27 (65.6%) | 0.105 |
Clopidogrel | 161 (95.4%) | 40 (98.2%) | 0.334 |
Statins | 160 (94.5%) | 40 (98.2%) | 0.662 |
β‐Blockers | 155 (91.5%) | 36 (86.6%) | 0.434 |
Infarct vessel | |||
LAD | 92 (54.4%) | 19 (46.7%) | 0.773 |
LCX | 19 (11.2%) | 5 (13.3%) | 0.984 |
RCA | 58 (34.4%) | 16 (40.0%) | 0.907 |
TIMI flow grade 0 at baseline | 114 (67.2%) | 31 (76.7%) | 0.314 |
Multivessel coronary disease | 52 (31.1%) | 10 (25.2%) | 0.623 |
Stent implantation | 161 (95.2%) | 40 (97.3%) | 0.944 |
Inflation pressure (atm) | 11.2 ± 2.8 | 10.8 ± 1.2 | 0.607 |
High thrombus burden | 59 (35.2%) | 30 (73.3%) | 0.001 |
MACCE | 9 (5.6%) | 7 (16.7%) | 0.039 |
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CRP, C‐reactive protein; LAD, left anterior descending artery; LCX, left circumflex artery; LDL‐C, low‐density lipoprotein cholesterol; MACCE, major adverse cardiac and cerebrovascular events; RCA, right coronary artery; TIMI, thrombolysis in myocardial infarction, WBC, white blood count